UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
___________________________
FORM 8-K
___________________________
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): June 26, 2020
___________________________
ACCELERON PHARMA INC.
(Exact name of Registrant as specified in its charter)
|
| | | | | |
| Delaware | | 001-36065 | | 27-0072226 |
(State or other jurisdiction of incorporation) | | (Commission File Number) | | (I.R.S. Employer Identification Number)
|
| 128 Sidney Street | | | | |
| Cambridge, | MA | | | | 02139 |
(Address of principal executive offices) | | | | (Zip Code) |
Registrant’s telephone number, including area code: (617) 649-9200
Not Applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Exchange Act:
|
| | |
| Title of each class | Ticker Symbol(s) | Name of each exchange on which registered |
| Common Stock, $0.001 per share | XLRN | The Nasdaq Global Market |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 8.01 Other Events.
On June 26, 2020, Acceleron Pharma Inc. and Bristol Myers Squibb announced that the European Commission has approved REBLOZYL® (luspatercept) for the treatment of:
| |
| • | Adult patients with transfusion-dependent anemia due to very low-, low- and intermediate-risk myelodysplastic syndromes (MDS) with ring sideroblasts, who had an unsatisfactory response or are ineligible for erythropoietin-based therapy. |
| |
| • | Adult patients with transfusion-dependent anemia associated with beta thalassemia. |
REBLOZYL is the first and only erythroid maturation agent approved in the European Union, representing a new class of therapy for eligible patients. This approval is based on data from the pivotal Phase 3 MEDALIST and BELIEVE studies, evaluating the ability of REBLOZYL to effectively address anemia associated with MDS and beta thalassemia, respectively.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
| | |
| | ACCELERON PHARMA INC. |
| | |
| | |
| | By: | /s/ Adam M. Veness, Esq. |
| | | Adam M. Veness, Esq. |
| | | Senior Vice President, General Counsel and Secretary |
| | | |
| Date: June 26, 2020 | | |
